Journal Club 2025

journal club image

Next HOPA Journal Club

Tuesday, March 8, 2025 at 2 p.m. Central Time

Listen to critical evaluations of hematology/oncology pharmacy publications presented by PGY2 Oncology Residents.

Click here to register for March's Journal Club!

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Linn Allworth, PharmD, PGY-2 Oncology Pharmacy Resident

University of VA Health System, Charlottesville, VA

Article:

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

H. Madelleine Foster, PharmD, PGY-2 Oncology Pharmacy Resident

Johns Hopkins Hospital, Baltimore, MD

Article:

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Reserve your spot for March's Journal Club!

Want to be a Journal Club Presenter?

The next call for the January-June 2025 session speakers is currently closed. Stay tuned for future opportunities.

Featured Articles

CanerBuddy app

Advocacy

HOPA, Bone Marrow & Cancer Foundation, and Walgreens Specialty Unite to Provide Oncology Pharmacy Education

February 07, 2025

HOPA, the Bone Marrow & Cancer Foundation (BMCF), and Walgreens Specialty Pharmacy have partnered on digital outreach resources and tools to support patients who are navigating the complexities of cancer treatment.

Membership

We Remain Committed to the Oncology Pharmacy Community and All Cancer Patients

February 06, 2025

The HOPA Board monitors recent Executive Orders and reaffirms the association's commitment to supporting our community of hematology/oncology pharmacists and all patients with cancer.

Pills photo

Tools and Resources

Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program

February 04, 2025

The HOPA OCC, with the participation of ASCO Quality Training Programs, has developed practice-based tools to aid in developing and improving initiatives and the care of patients receiving oral anticancer agents (OAAs).